Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Chronic allergic diseases such as atopic dermatitis (eczema) and asthma are complex, multi-factorial diseases with an underlying aberrant inflammatory response. Existing therapeutic approaches are targeted at suppressing this inflammatory response (such as glucocorticosteroids and β-adrenoreceptor agonists), however, these therapies are limited to treating the symptoms and treatment duration is limited as a result of unfavorable adverse effects.
HT-004 is a potential disease-modifying agent that uses gene therapy-targeted methods to reduce mast cell responses to immunoglobulin E (IgE)-directed antigens, which is one of the key mechanisms in the pathophysiology of asthma, atopic dermatitis, and other allergic diseases. HT-004 is currently under investigation for treatment of asthma using inhalational administration.
HT-004 is in the early preclinical stage of development. The preclinical studies are being executed under the guidance of Dr. Glenn Cruse, PhD at North Carolina State University. Dr. Cruse is also a member of the Hoth Scientific Advisory board.
Expected initial results Q1 2021